MiNK Therapeutics Inc. Common Stock (INKT)

About INKT

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

15

Website

www.minktherapeutics.com

Fundamentals

1-day range

$11.06$11.45

Market cap

$53.26M

P/E (trailing)

—

P/E (forward)

-4.32

EPS (trailing)

$-2.84

Dividend yield

—

Beta

0.53

Avg. volume

17.7K

Forecasts

2 analyst ratings

MiNK Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• INKT

  MiNK Therapeutics Inc. Common Stock

  $11.43

  ▼ 2.16%
  Market cap $53.26MP/E —
  $8.48$16.98
• SCLX

  Scilex Holding Company Common Stock

  $5.42

  ▼ 2.69%
  Market cap $55.70MP/E —
  $4.2$34.27
• OKYO

  OKYO Pharma Limited Ordinary Shares

  $1.67

  ▲ 7.74%
  Market cap $56.51MP/E —
  $1.34$3.2
• TIL

  Instil Bio Inc. Common Stock

  $7.58

  ▼ 3.56%
  Market cap $48.97MP/E —
  $5.67$33.83
• EXOZ

  eXoZymes Inc. Common Stock

  $7.17

  ▼ 0.10%
  Market cap $47.57MP/E —
  $4.35$18.4
• TVGN

  Tevogen Inc. Common Stock

  $6.89

  ▲ 2.07%
  Market cap $45.04MP/E —
  $3.64$49.5
• XTNT

  Xtant Medical Holdings Inc. Common Stock

  $0.4055

  ▲ 22.88%
  Market cap $61.72MP/E 23.84
  $0.2702$0.95

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research Symposium - Slideshow
  SeekingAlpha · 8/13/2026
• MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript
  benzinga · 8/13/2026
• MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript
  Benzinga · 8/13/2026
• MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate
  Benzinga · 8/13/2026

• Barbara Ryan · June 4, 2026 · Sale

  1.0K @ $12.8
• Barbara Ryan · June 4, 2026 · Sale

  500 @ $12.68
• John Bradley Holcomb · June 1, 2026 · Grant

  1.1K @ $12.38
• Peter Behner · June 1, 2026 · Grant

  1.3K @ $12.38
• Barbara Ryan · June 1, 2026 · Grant

  1.4K @ $12.38
• Brian Corvese · June 1, 2026 · Grant

  1.4K @ $12.38
• Ulf Wiinberg · June 1, 2026 · Grant

  1.1K @ $12.38
• Barbara Ryan · March 10, 2026 · Sale

  500 @ $15.57
• Barbara Ryan · March 10, 2026 · Sale

  300 @ $15.28
• Barbara Ryan · March 9, 2026 · Sale

  200 @ $10.17
• John Bradley Holcomb · March 2, 2026 · Grant

  1.2K @ $10.9
• Peter Behner · March 2, 2026 · Grant

  1.5K @ $10.9
• Barbara Ryan · March 2, 2026 · Grant

  1.6K @ $10.9
• Brian Corvese · March 2, 2026 · Grant

  1.6K @ $10.9
• Ulf Wiinberg · March 2, 2026 · Grant

  1.3K @ $10.9

Institutional Ownership

March 31, 2026

Total shares held

117.5K

Total value held

$1.24M

Institutional holders

20